Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Transmedics Group (TMDX) stock in plain English

Free brief · no signupStart here
TMDXPublished Nov 17, 2026
Transmedics Group Inc
Healthcare · Medical Devices
Manufactures portable organ perfusion systems that pump warm, oxygenated blood through donor organs during transit.
Assets:
Aviation FleetOwns and operates dedicated aircraft for nationwide donor organ transport.
Organ Care SystemProvides portable warm-perfusion modules for donor lungs, hearts, and livers.
Andover HeadquartersRuns a manufacturing and operational headquarters facility in Andover, Massachusetts.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-2.50%$94.02
$3.27B
25.8×
$727.32M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TMDX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Transmedics Group (TMDX) do?

Transmedics Group Inc (TMDX) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures portable organ perfusion systems that pump warm, oxygenated blood through donor organs during transit. Keeps donor organs warm and functioning during transport using portable perfusion machines and its own aviation fleet. It is worth $3.27B on the market and sold $727.32M over the last year.

Market cap
$3.27B
P/E ratio
25.8×
Annual sales
$727.32M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 17, 2026

Brands and businesses behind TMDX

  • Organ Care System: Sells warm perfusion machines and single-use perfusion sets used to preserve donor hearts, lungs, and livers.
  • National OCS Program: Provides turnkey organ retrieval logistics and clinical management services to transplant hospitals for a per-mission fee.

TMDX’s flags, in plain English

Each flag is a number from Transmedics Group’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 88.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Wide Gross Margin

Gross margin of 57.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Profit with Caveats

Bottom-line profit of $144M in the 12 months to Sep 30, 2026, next to $86M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about TMDX

How big is Transmedics Group?

Transmedics Group’s market cap is $3.27B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $727.32M: what customers paid the company over the last year, before any costs.

What is TMDX’s P/E ratio?

TMDX’s P/E ratio is 25.8×. Investors pay about 25.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with TMDX?

The company relies on a single proprietary hardware platform across all three of its approved organ transplant markets. That is one risk on Transmedics Group’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Transmedics Group’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TMDX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card